15 studies found for:    S1107
Show Display Options
Rank Status Study
1 Active, not recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
Conditions: Childhood Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Tivantinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
2 Completed A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy
Condition: Opioid Induced Constipation
Interventions: Drug: Placebo once daily;   Drug: 0.1 mg of S-297995 once daily;   Drug: 0.2 mg of S-297995 once daily;   Drug: 0.4 mg of S-297995 once daily
3 Active, not recruiting XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: SP;   Drug: XP
4 Completed
Has Results
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: clofarabine;   Drug: temsirolimus
5 Completed
Has Results
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Condition: Stroke
Interventions: Drug: Aggrenox;   Drug: Clopidogrel placebo;   Drug: Micardis;   Drug: Aggrenox placebo;   Drug: Clopidogrel;   Drug: Micardis placebo
6 Completed
Has Results
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Condition: Atrial Fibrillation
Interventions: Drug: dabigatran dose 1;   Drug: dabigatran dose 2
7 Completed
Has Results
For the Health of Our Children--Clinic Based Treatment of Childhood Obesity
Condition: Obesity
Intervention: Behavioral: Behavioral counseling
8 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
9 Completed
Has Results
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
10 Recruiting A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)
Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg;   Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg;   Drug: Mometasone Furoate MDI 100 mcg;   Drug: Mometasone Furoate MDI 200 mcg;   Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI;   Drug: Prednisone/prednisolone
11 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
12 Completed Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Condition: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: CHF1535 + CHF5992 dose 1 BID;   Drug: CHF1535 + CHF5992  dose2 BID;   Drug: CHF1535 daily dose
13 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
14 Recruiting A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
15 Active, not recruiting
Has Results
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab

Indicates status has not been verified in more than two years